Key facts
- It has raised $50K; the latest was Grant ($10K) in Apr 2025.
- Notable investors include BMH Beteiligungs-Managementgesellschaft Hessen, BioVaria, Business Angels Club Berlin-Brandenburg, Bürkert Fluid Control Systems, ESA Commercialisation Gateway — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Green Elephant Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Green Elephant Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Green Elephant Biotech
Operator of a biotechnology platform intended to produce laboratory supplies from sustainable materials. The company's platform assists research and production companies in the biotech and pharmaceutical industries in reducing their carbon dioxide emissions and developing cultivation systems for large-scale cell cultivation, enabling healthcare companies to replace single-use plastic labware with products made from sustainable materials and efficiently reduce the ecological footprint of their work.
- Sector
- Healthcare
- HQ
- Giessen, Germany
- Founded
- 2017
- Employees
- 20
- Website
- greenelephantbiotech.com/
- Ownership
- Privately Held (backing)
Green Elephant Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Green Elephant Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Green Elephant Biotech in its N-PORT filings yet. We sweep new filings monthly.